Clinical reference Biomarker Directory
Back to directory

Antineutrophil cytoplasmic antibodies against proteinase 3

Emerging

PR3-ANCA is more specifically associated with granulomatosis with polyangiitis than the MPO-ANCA/p-ANCA pattern.

Also known as PR3-ANCA c-ANCA (cytoplasmic pattern) anti-proteinase 3 antibody
In plain language

This is the specific antibody type usually behind the "cytoplasmic" ANCA staining pattern, more often linked to one particular type of small-vessel vasculitis than the "perinuclear" pattern discussed earlier, though both fall under the same current treatment guidelines.

Biomarker & context

PR3-ANCA (proteinase 3-ANCA) is the antigen-specific counterpart to the cytoplasmic (c-ANCA) immunofluorescence staining pattern, one of the two major ANCA subtypes alongside MPO-ANCA (the perinuclear/p-ANCA pattern discussed earlier).

What it indicates

PR3-ANCA is more specifically associated with granulomatosis with polyangiitis, while MPO-ANCA leans toward microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis — the antigen specificity carries somewhat more prognostic and phenotypic meaning than the immunofluorescence pattern alone.

Diagnosis & clinical testing

Measured via antigen-specific immunoassay, ideally alongside or instead of immunofluorescence pattern determination, since current best practice emphasizes antigen-specific testing (MPO vs. PR3) over pattern-only reporting for optimal clinical correlation.

Guiding treatment

Both PR3-ANCA and MPO-ANCA-associated vasculitis fall under the same current 2024 KDIGO ANCA-vasculitis treatment guidance discussed earlier; a compatible clinical presentation with positive PR3-ANCA serology often supports starting treatment without waiting for kidney biopsy confirmation in rapidly deteriorating patients.

Clinical significance

Current best practice favors antigen-specific (PR3 vs. MPO) testing over immunofluorescence pattern alone for clinical correlation.

References
  1. KDIGO. (2024). Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.